Skip to main content
. Author manuscript; available in PMC: 2022 Oct 18.
Published in final edited form as: Mol Cancer Ther. 2022 Aug 2;21(8):1306–1317. doi: 10.1158/1535-7163.MCT-21-0598

Figure 5: G3MB tumors treated with the combination of ribociclib and gemcitabine have a higher differentiation score and remain of the G3 subgroup.

Figure 5:

Analysis of the expression of genes in the G3/G4 differentiation pathways compared to those expressed in primary human MB tumors after RNA sequencing from PDOX MB002 (A, B) or mouse tumor #2416 (C, D) after treatment with vehicle, gemcitabine, ribociclib and combination of gemcitabine and ribociclib. (A, C) G3/G4 differentiation score (Mann-Whitney test, gemcitabine + ribociclib versus vehicle). (B, D) Clustering of the tumors with primary human G3 and G4 MB tumors.